{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:01:31Z","timestamp":1790085691742,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81901229"],"award-info":[{"award-number":["81901229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00415-025-13125-w","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T20:22:50Z","timestamp":1746908570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Relapse risk after rituximab discontinuation in neuromyelitis optica spectrum disorders: a multi-center retrospective cohort study"],"prefix":"10.1007","volume":"272","author":[{"given":"Shengfei","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuming","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1932-3737","authenticated-orcid":false,"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"13125_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","volume":"18","author":"E Carnero Contentti","year":"2021","unstructured":"Carnero Contentti E, Correale J (2021) Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflammation 18:208. https:\/\/doi.org\/10.1186\/s12974-021-02249-1","journal-title":"J Neuroinflammation"},{"key":"13125_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","volume":"20","author":"M Levy","year":"2021","unstructured":"Levy M, Fujihara K, Palace J (2021) New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 20:60\u201367. https:\/\/doi.org\/10.1016\/S1474-4422(20)30392-6","journal-title":"Lancet Neurol"},{"key":"13125_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T K\u00fcmpfel","year":"2024","unstructured":"K\u00fcmpfel T, Giglhuber K, Aktas O et al (2024) Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) \u2013 revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. J Neurol 271:141\u2013176. https:\/\/doi.org\/10.1007\/s00415-023-11910-z","journal-title":"J Neurol"},{"key":"13125_CR4","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1007\/s00415-023-11641-1","volume":"270","author":"Z Yin","year":"2023","unstructured":"Yin Z, Qiu Y, Duan A et al (2023) Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis. J Neurol 270:2950\u20132963. https:\/\/doi.org\/10.1007\/s00415-023-11641-1","journal-title":"J Neurol"},{"key":"13125_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","volume":"17","author":"SJ Pittock","year":"2021","unstructured":"Pittock SJ, Zekeridou A, Weinshenker BG (2021) Hope for patients with neuromyelitis optica spectrum disorders \u2014 from mechanisms to trials. Nat Rev Neurol 17:759\u2013773. https:\/\/doi.org\/10.1038\/s41582-021-00568-8","journal-title":"Nat Rev Neurol"},{"key":"13125_CR6","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1177\/1352458519837924","volume":"25","author":"DM Wingerchuk","year":"2019","unstructured":"Wingerchuk DM (2019) Disease-modifying therapies should be stopped in NMOSD patients in remission \u2013 commentary. Mult Scler 25:1220\u20131222. https:\/\/doi.org\/10.1177\/1352458519837924","journal-title":"Mult Scler"},{"key":"13125_CR7","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1177\/1352458519829694","volume":"25","author":"E Shosha","year":"2019","unstructured":"Shosha E (2019) Disease-modifying therapies should be stopped in NMOSD patients in remission \u2013 yes. Mult Scler 25:1217\u20131218. https:\/\/doi.org\/10.1177\/1352458519829694","journal-title":"Mult Scler"},{"key":"13125_CR8","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1080\/14712598.2022.2145879","volume":"22","author":"A Vishnevetsky","year":"2022","unstructured":"Vishnevetsky A, Kaplan TB, Levy M (2022) Transitioning immunotherapy in neuromyelitis optica spectrum disorder \u2013 when and how to switch. Expert Opin Biol Ther 22:1393\u20131404. https:\/\/doi.org\/10.1080\/14712598.2022.2145879","journal-title":"Expert Opin Biol Ther"},{"key":"13125_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000947","volume":"8","author":"S-H Kim","year":"2021","unstructured":"Kim S-H, Jang H, Park NY et al (2021) Discontinuation of immunosuppressive therapy in patients with neuromyelitis optica spectrum disorder with Aquaporin-4 antibodies. Neurol Neuroimmunol Neuroinflamm 8:e947. https:\/\/doi.org\/10.1212\/NXI.0000000000000947","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13125_CR10","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1111\/ene.15425","volume":"29","author":"R Li","year":"2022","unstructured":"Li R, Li C, Huang Q et al (2022) Immunosuppressant and neuromyelitis optica spectrum disorder: optimal treatment duration and risk of discontinuation. Eur J Neurol 29:2792\u20132800. https:\/\/doi.org\/10.1111\/ene.15425","journal-title":"Eur J Neurol"},{"key":"13125_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/NRL.0000000000000095","volume":"21","author":"J-W Hyun","year":"2016","unstructured":"Hyun J-W, Kim G, Kim Y et al (2016) Severe relapse after cessation of immunosuppressive therapy in a patient with neuromyelitis optica spectrum disorder. Neurologist 21:97\u201398. https:\/\/doi.org\/10.1097\/NRL.0000000000000095","journal-title":"Neurologist"},{"key":"13125_CR12","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1177\/0883073814553974","volume":"30","author":"K Weinfurtner","year":"2015","unstructured":"Weinfurtner K, Graves J, Ness J et al (2015) Prolonged remission in neuromyelitis optica following cessation of rituximab treatment. J Child Neurol 30:1366\u20131370. https:\/\/doi.org\/10.1177\/0883073814553974","journal-title":"J Child Neurol"},{"key":"13125_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","volume":"19","author":"F Gao","year":"2019","unstructured":"Gao F, Chai B, Gu C et al (2019) Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol 19:36. https:\/\/doi.org\/10.1186\/s12883-019-1261-2","journal-title":"BMC Neurol"},{"key":"13125_CR14","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s00415-019-09180-9","volume":"266","author":"V Shaygannejad","year":"2019","unstructured":"Shaygannejad V, Fayyazi E, Badihian S et al (2019) Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study. J Neurol 266:642\u2013650. https:\/\/doi.org\/10.1007\/s00415-019-09180-9","journal-title":"J Neurol"},{"key":"13125_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102727","volume":"20","author":"O Mirmosayyeb","year":"2021","unstructured":"Mirmosayyeb O, Shaygannejad V, Barzegar M, Nehzat N, Ghajarzadeh M (2021) Efficacy and safety of rituximab in treating patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis. Autoimmun Rev 20:102727. https:\/\/doi.org\/10.1016\/j.autrev.2020.102727","journal-title":"Autoimmun Rev"},{"key":"13125_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.101933","volume":"40","author":"Q Lu","year":"2020","unstructured":"Lu Q, Luo J, Hao H et al (2020) A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 40:101933. https:\/\/doi.org\/10.1016\/j.msard.2020.101933","journal-title":"Mult Scler Relat Disord"},{"key":"13125_CR17","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001179","volume":"9","author":"S-H Kim","year":"2022","unstructured":"Kim S-H, Park NY, Kim KH, Hyun J-W, Kim HJ (2022) Rituximab-induced hypogammaglobulinemia and risk of infection in neuromyelitis optica spectrum disorders: A 14-year real-life experience. Neurol Neuroimmunol Neuroinflamm 9:e1179. https:\/\/doi.org\/10.1212\/NXI.0000000000001179","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13125_CR18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","volume":"66","author":"K Hawker","year":"2009","unstructured":"Hawker K, O\u2019Connor P, Freedman MS et al (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66:460\u2013471. https:\/\/doi.org\/10.1002\/ana.21867","journal-title":"Ann Neurol"},{"key":"13125_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"key":"13125_CR20","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/00207454.2016.1242587","volume":"127","author":"J Lin","year":"2017","unstructured":"Lin J, Xue B, Li X, Xia J (2017) Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future. Int J Neurosci 127:735\u2013744. https:\/\/doi.org\/10.1080\/00207454.2016.1242587","journal-title":"Int J Neurosci"},{"key":"13125_CR21","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00415-016-8188-y","volume":"263","author":"P Annovazzi","year":"2016","unstructured":"Annovazzi P, Capobianco M, Moiola L et al (2016) Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. J Neurol 263:1727\u20131735. https:\/\/doi.org\/10.1007\/s00415-016-8188-y","journal-title":"J Neurol"},{"key":"13125_CR22","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","volume":"75","author":"M Granqvist","year":"2018","unstructured":"Granqvist M, Boremalm M, Poorghobad A et al (2018) Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol 75:320\u2013327. https:\/\/doi.org\/10.1001\/jamaneurol.2017.4011","journal-title":"JAMA Neurol"},{"key":"13125_CR23","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S1474-4422(24)00077-2","volume":"23","author":"BAC Cree","year":"2024","unstructured":"Cree BAC, Kim HJ, Weinshenker BG et al (2024) Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial. Lancet Neurol 23:588\u2013602. https:\/\/doi.org\/10.1016\/S1474-4422(24)00077-2","journal-title":"Lancet Neurol"},{"key":"13125_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103730","volume":"60","author":"M Tahara","year":"2022","unstructured":"Tahara M, Oeda T, Okada K et al (2022) Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration. Mult Scler Relat Disord 60:103730. https:\/\/doi.org\/10.1016\/j.msard.2022.103730","journal-title":"Mult Scler Relat Disord"},{"key":"13125_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.msard.2012.12.001","volume":"2","author":"B Banwell","year":"2013","unstructured":"Banwell B, Giovannoni G, Hawkes C, Lublin F (2013) Editors\u2019 welcome and a working definition for a multiple sclerosis cure. Mult Scler Relat Disord 2:65\u201367. https:\/\/doi.org\/10.1016\/j.msard.2012.12.001","journal-title":"Mult Scler Relat Disord"},{"key":"13125_CR26","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.maturitas.2010.08.003","volume":"67","author":"CM Gameiro","year":"2010","unstructured":"Gameiro CM, Rom\u00e3o F, Castelo-Branco C (2010) Menopause and aging: changes in the immune system\u2014a review. Maturitas 67:316\u2013320. https:\/\/doi.org\/10.1016\/j.maturitas.2010.08.003","journal-title":"Maturitas"},{"key":"13125_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2020.100021","volume":"2","author":"D-C Tian","year":"2020","unstructured":"Tian D-C, Li Z, Yuan M et al (2020) Incidence of neuromyelitis optica spectrum disorder (NMOSD) in China: a national population-based study. Lancet Reg Health West Pac 2:100021. https:\/\/doi.org\/10.1016\/j.lanwpc.2020.100021","journal-title":"Lancet Reg Health West Pac"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13125-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13125-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13125-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T13:25:27Z","timestamp":1749907527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13125-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["13125"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13125-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"1 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"387"}}